Emerging in the landscape of excess body fat therapy, retatrutide represents a distinct method. Beyond many available medications, retatrutide works as a twin agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The dual activation encourages several beneficial effe